AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26356160 — intervention group
Group type: COMPARATOR
Intervention: Zonisamid and Placebo (side effects)
Number of subjects: 207
Study 23423302 — intervention group
Group type: COMPARATOR
Intervention: L-arginine (ARG) 6 g
Number of subjects: 23
Study 23423302 — intervention group
Group type: COMPARATOR
Intervention: L-arginine (ARG) 6 g plus 25 g carbohydrate (ARG + CHO)
Number of subjects: 23
Study 20872778 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-742457 35 mg/day
Number of subjects: 198
Study 20872778 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil 10 mg/day
Number of subjects: 198
Study 20872778 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 198
Study 19570158 — intervention group
Group type: EXPERIMENTAL
Intervention: Res-Care intervention
Number of subjects: 487
Study 16684436 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 203
Study 16684436 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 203
Study 15194366 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg/dose every 14 days for five doses (group I, n = 107)
Number of subjects: 297
Study 15194366 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab 2 mg/kg/dose every 14 days for two doses (group II, n = 112)
Number of subjects: 297
Study 15194366 — intervention group
Group type: COMPARATOR
Intervention: No-antibody induction (group III, n = 78)
Number of subjects: 297
Study 15194366 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups received tacrolimus, mycophenolate mofetil, and steroids for maintenance immunosuppression
Number of subjects: 297
Study 15194366 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 297
Study 10673485 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed Index Medicus (n = 32)
Number of subjects: 103
Study 10673485 — intervention group
Group type: EXPERIMENTAL
Intervention: Grateful Med (n = 12)
Number of subjects: 103
Study 10673485 — intervention group
Group type: COMPARATOR
Intervention: CD-ROM (n = 31)
Number of subjects: 103
Study 9085314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (HDE)
Number of subjects: 140
Study 9085314 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose epinephrine (SDE)
Number of subjects: 140
Study 1489123 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (10 microM to 50 microM)
Number of subjects: 0
Study 1489123 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lidocaine (20 mg and 80 mg from nebulized solutions)
Number of subjects: 0
Study 1489123 — intervention group
Group type: COMPARATOR
Intervention: Citric acid (nebulized solutions 0.125 to 32%)
Number of subjects: 0
Study 3993874 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume epidural morphine (2 mg in 1 ml saline) administered to Group II patients upon complaint of worst pain
Number of subjects: 50
Study 3993874 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume epidural morphine (2 mg in 1 ml saline) administered to Group III patients after extubation but before pain complaint
Number of subjects: 50
Study 3993874 — intervention group
Group type: COMPARATOR
Intervention: Standard volume epidural morphine (2 mg in 10 ml saline) administered to Group I patients upon complaint of worst pain
Number of subjects: 50
Study 30985540 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (60 mg/kg)
Number of subjects: 60
Study 30985540 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% saline, 100 ml)
Number of subjects: 60
Study 30171334 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care intervention
Number of subjects: 92
Study 30171334 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 92
Study 28400374 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with intraocular lens (IOL) implantation plus goniosynechialysis (phaco-GSL)
Number of subjects: 26
Study 28400374 — intervention group
Group type: COMPARATOR
Intervention: Phacoemulsification with intraocular lens (IOL) implantation only (phaco)
Number of subjects: 26
Study 25316559 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic (400 mg garlic and 1 mg allicin)
Number of subjects: 44
Study 25316559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23595874 — intervention group
Group type: EXPERIMENTAL
Intervention: 850 mg pure theobromine (TB)
Number of subjects: 152
Study 23595874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa intervention (CC)
Number of subjects: 152
Study 23595874 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine and cocoa intervention (TB+CC)
Number of subjects: 152
Study 23595874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 21694628 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zopiclone
Number of subjects: 16
Study 21694628 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zopiclone
Number of subjects: 16
Study 21694628 — intervention group
Group type: COMPARATOR
Intervention: 50 g ethanol
Number of subjects: 16
Study 21694628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18269387 — intervention group
Group type: COMPARATOR
Intervention: 5 mg hyperbaric bupivacaine (B5C0)
Number of subjects: 75
Study 18269387 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg hyperbaric bupivacaine with 15 microg clonidine (B5C15)
Number of subjects: 75
Study 18269387 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg hyperbaric bupivacaine with 30 microg clonidine (B5C30)
Number of subjects: 75
Study 16926554 — intervention group
Group type: EXPERIMENTAL
Intervention: NIHSS score cut point of >=15
Number of subjects: 385
Study 12616034 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 IU/kg rhGH given 3 times a week for the first 4 weeks and 0.25 IU/kg thereafter
Number of subjects: 19
Study 10710462 — intervention group
Group type: EXPERIMENTAL
Intervention: Gutta‐Condensor
Number of subjects: 50
Study 10710462 — intervention group
Group type: EXPERIMENTAL
Intervention: MecaShaper
Number of subjects: 50
Study 10710462 — intervention group
Group type: EXPERIMENTAL
Intervention: K‐type ultrasonic file
Number of subjects: 50
Study 10710462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentulo
Number of subjects: 50
Study 10710462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pastinject
Number of subjects: 50
Study 9415501 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency lesioning at 67 degrees C
Number of subjects: 61
Study 9415501 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency lesioning at 40 degrees C (Control)
Number of subjects: 61
Study 7506471 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (hGH) treatment (0.1 IU.kg‐1 body wt.day‐1 for 7 days)
Number of subjects: 16
Study 7506471 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (hGH) treatment
Number of subjects: 16
Study 2952826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam
Number of subjects: 172
Study 2952826 — intervention group
Group type: COMPARATOR
Intervention: Cefoperazone
Number of subjects: 172
Study 29985440 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug users (including digoxin and sotalol)
Number of subjects: 78615
Study 29985440 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 78615
Study 29985440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 78615
Study 29985440 — intervention group
Group type: COMPARATOR
Intervention: Non-users of antiarrhythmic drugs
Number of subjects: 78615
Study 28264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture manipulation at 1 Hz
Number of subjects: 0
Study 28264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture manipulation at 2 Hz
Number of subjects: 0
Study 28264722 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture manipulation at 3 Hz
Number of subjects: 0
Study 28264722 — intervention group
Group type: COMPARATOR
Intervention: Control group (needles inserted without manipulation)
Number of subjects: 0
Study 24579970 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil in addition to routine treatment
Number of subjects: 80
Study 24579970 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (control group)
Number of subjects: 80
Study 23536997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 180
Study 23536997 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 180
Study 23536997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 20070415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid 5 mg
Number of subjects: 3887
Study 18847584 — intervention group
Group type: EXPERIMENTAL
Intervention: Second dose of misoprostol 800 mcg vaginally
Number of subjects: 1972
Study 16373904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 54
Study 16373904 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 12611026 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional restoration early intervention (n = 22)
Number of subjects: 124
Study 12611026 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group (n = 48)
Number of subjects: 124
Study 12611026 — intervention group
Group type: COMPARATOR
Intervention: Low-risk subjects (n = 54)
Number of subjects: 124
Study 12611026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost savings associated with early intervention
Number of subjects: 124
Study 11314870 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL ECT)
Number of subjects: 0
Study 11314870 — intervention group
Group type: COMPARATOR
Intervention: Unilateral ECT (UL ECT)
Number of subjects: 0
Study 7636923 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternity waiting home
Number of subjects: 6438
Study 7636923 — intervention group
Group type: COMPARATOR
Intervention: Home delivery
Number of subjects: 6438
Study 2677624 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline delivered by Nebuhaler
Number of subjects: 27
Study 2677624 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline delivered by nebulizer
Number of subjects: 27
Study 687049 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted positioning
Number of subjects: 20
Study 687049 — intervention group
Group type: COMPARATOR
Intervention: Supine position (control)
Number of subjects: 20
Study 31415825 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) administration
Number of subjects: 513
Study 31415825 — intervention group
Group type: COMPARATOR
Intervention: sBP decline of at least 5 mmHg
Number of subjects: 513
Study 30943196 — intervention group
Group type: EXPERIMENTAL
Intervention: ECI visible (change of 12%)
Number of subjects: 98
Study 30943196 — intervention group
Group type: EXPERIMENTAL
Intervention: CF visible (range 5‐40g)
Number of subjects: 98
Study 30943196 — intervention group
Group type: COMPARATOR
Intervention: Control group (ECI not visible)
Number of subjects: 98
Study 28103816 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assessment instrument (Montgomery-Asberg Depression Rating Scale) used in recurrent consultations with GPs, treatment as usual (TAU) for 3 months, with at least 4 visits.
Number of subjects: 258
Study 28103816 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) without the self-assessment instrument.
Number of subjects: 258
Study 25179540 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-language HIV/AIDS and HIV testing video
Number of subjects: 150
Study 25179540 — intervention group
Group type: COMPARATOR
Intervention: Orally-delivered HIV/AIDS and HIV testing information
Number of subjects: 150
Study 25179540 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-language HIV/AIDS and HIV testing video (lower health literacy participants)
Number of subjects: 150
Study 25179540 — intervention group
Group type: COMPARATOR
Intervention: Orally-delivered HIV/AIDS and HIV testing information (lower health literacy participants)
Number of subjects: 150
Study 21905158 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity counseling (PA group, n = 20) for 3 months via telephone, including weekly PA tip sheets.
Number of subjects: 46
Study 21905158 — intervention group
Group type: COMPARATOR
Intervention: Contact control (control group, n = 26).
Number of subjects: 46
Study 21992075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib plus letrozole (L + Let)
Number of subjects: 219
Study 21992075 — intervention group
Group type: COMPARATOR
Intervention: Letrozole monotherapy (Let)
Number of subjects: 219
Study 19090876 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5-25 mg/d
Number of subjects: 33567
Study 19090876 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5-10 mg/d
Number of subjects: 33567
Study 19090876 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10-40 mg/d
Number of subjects: 33567
Study 16542132 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention
Number of subjects: 1207
Study 16542132 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1207
Study 12681034 — intervention group
Group type: EXPERIMENTAL
Intervention: GyneFix
Number of subjects: 2
Study 12681034 — intervention group
Group type: COMPARATOR
Intervention: Gyne-T380S
Number of subjects: 2
Study 11023764 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated children (first vaccination on the 60th day of life)
Number of subjects: 496
Study 11023764 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated children (first vaccination on the 90th day of life)
Number of subjects: 496
Study 9032702 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose solution (0.1 kcal ml‐1)
Number of subjects: 6
Study 9032702 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein (0.7 kcal ml‐1)
Number of subjects: 6
Study 9032702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pea peptide hydrolysate (0.2 kcal ml‐1)
Number of subjects: 6
Study 9032702 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey peptide hydrolysate (0.2 kcal ml‐1)
Number of subjects: 6
Study 7690583 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxy-L-tryptophan (5-HTP, 10 micrograms kg-1 min-1)
Number of subjects: 5
Study 7690583 — intervention group
Group type: EXPERIMENTAL
Intervention: gamma-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP, 16.6 micrograms kg-1 min-1)
Number of subjects: 5
Study 7690583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 3538367 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-drug combination therapy (vincristine, carmustine, alkylating agents, and prednisone)
Number of subjects: 67
Study 3538367 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-drug combination therapy
Number of subjects: 67
Study 3538367 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-drug combination therapy
Number of subjects: 67
Study 3538367 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy after remission
Number of subjects: 67
Study 3538367 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued therapy after remission
Number of subjects: 67
Study 3538367 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy vs Discontinued therapy
Number of subjects: 67
Study 30092324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg weekly for 16 weeks)
Number of subjects: 178
Study 30092324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 29887386 — intervention group
Group type: EXPERIMENTAL
Intervention: True Colic Cohort
Number of subjects: 281
Study 29887386 — intervention group
Group type: COMPARATOR
Intervention: No Colic Cohort
Number of subjects: 281
Study 27716697 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) 30 mg/kg in 500 cc normal saline
Number of subjects: 80
Study 27716697 — intervention group
Group type: COMPARATOR
Intervention: Control group (500 cc normal saline)
Number of subjects: 80
Study 27716697 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 80
Study 24684105 — intervention group
Group type: EXPERIMENTAL
Intervention: EA + GA
Number of subjects: 20
Study 24684105 — intervention group
Group type: COMPARATOR
Intervention: GA
Number of subjects: 20
Study 23230645 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel (F) alone
Number of subjects: 73
Study 23230645 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride gel (F) combined with chlorhexidine varnishes (CHX)
Number of subjects: 73
Study 23230645 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 73
Study 20424456 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine treatment
Number of subjects: 107
Study 20424456 — intervention group
Group type: COMPARATOR
Intervention: Methadone treatment
Number of subjects: 107
Study 18402625 — intervention group
Group type: EXPERIMENTAL
Intervention: New prediction equations for lithium clearance (CL(Li)) for inpatients: CL(Li) = 0.932 + 0.185CL(Cr)
Number of subjects: 60
Study 18402625 — intervention group
Group type: EXPERIMENTAL
Intervention: New prediction equations for lithium clearance (CL(Li)) for outpatients: CL(Li) = 1.021 + 0.141CL(Cr)
Number of subjects: 60
Study 18402625 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose (inpatients, mg) = 350.15 + 289.92 (desired lithium level, mmol/L) + 0.84 (weight, kg) - 1.76 (age, years) + 34.43 [TCA, yes = 1, no = 0] + 62.1(CL(Cr), L/h) + 13.1 [BUN, mmol/L] + 40.9 (sex, male = 1, female = 0)
Number of subjects: 60
Study 18402625 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dose (outpatients, mg) = 784.92 + 530.22 (desired lithium level, mmol/L) + 8.61 (weight, kg) - 12.09 (age, years) - 11.14 (TCA, yes = 1, no = 0) - 7.63 (CL(Cr), L/h) - 42.62 (BUN, mmol/L) - 23.43 (sex, male = 1, female = 0)
Number of subjects: 60
Study 15808751 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of phVEGF-A(165)
Number of subjects: 80
Study 15808751 — intervention group
Group type: COMPARATOR
Intervention: Placebo plasmid
Number of subjects: 80
Study 12424582 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV/Hib vaccine
Number of subjects: 312
Study 12424582 — intervention group
Group type: COMPARATOR
Intervention: DTPa-IPV/Hib and HBV vaccines (comparator)
Number of subjects: 312
Study 10354290 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 38
Study 10354290 — intervention group
Group type: COMPARATOR
Intervention: Atgam
Number of subjects: 38
Study 8944196 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloured overlays
Number of subjects: 0
Study 12285561 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 applications of 36 mg quinacrine hydrochloride pellets during the proliferative phase of 3 consecutive menstrual cycles
Number of subjects: 60
Study 6234966 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg rosoxacin by mouth (group B)
Number of subjects: 200
Study 6234966 — intervention group
Group type: COMPARATOR
Intervention: 2 g spectinomycin administered intramuscularly (group A)
Number of subjects: 200
Study 31434583 — intervention group
Group type: EXPERIMENTAL
Intervention: Monaural pure tones presented at 25 dB
Number of subjects: 387
Study 31434583 — intervention group
Group type: EXPERIMENTAL
Intervention: LittlEars auditory questionnaire
Number of subjects: 387
Study 30409152 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenteric approach (arm B)
Number of subjects: 354
Study 30409152 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (arm A)
Number of subjects: 354
Study 26856225 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) therapy for obstructive sleep apnea.
Number of subjects: 0
Study 26856225 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral interventions to improve PAP compliance.
Number of subjects: 0
Study 26856225 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary team approaches in the studies (SleepTight and BestAIR).
Number of subjects: 0
Study 24877116 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit balance training
Number of subjects: 50
Study 24877116 — intervention group
Group type: COMPARATOR
Intervention: Usual balance therapy
Number of subjects: 50
Study 23210416 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stabilized stannous fluoride test dentifrice (SnF2)
Number of subjects: 27
Study 23210416 — intervention group
Group type: COMPARATOR
Intervention: Amine fluoride/stannous fluoride marketed control dentifrice (AmF/SnF2)
Number of subjects: 27
Study 20153389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 170
Study 20153389 — intervention group
Group type: COMPARATOR
Intervention: Corn-soy blend (CSB)
Number of subjects: 170
Study 20153389 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS) mixed with porridge
Number of subjects: 170
Study 18391643 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based aerobic exercise-training program (T)
Number of subjects: 90
Study 18391643 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 90
Study 16022953 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency revascularization (ERV)
Number of subjects: 87
Study 16022953 — intervention group
Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 87
Study 12225494 — intervention group
Group type: EXPERIMENTAL
Intervention: Parachute group (intensive psychosocial treatment and support)
Number of subjects: 253
Study 12225494 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to a small overnight crisis home
Number of subjects: 253
Study 12225494 — intervention group
Group type: COMPARATOR
Intervention: Historical comparison group
Number of subjects: 253
Study 12225494 — intervention group
Group type: COMPARATOR
Intervention: Prospective group
Number of subjects: 253
Study 10348530 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided stent deployment (group A)
Number of subjects: 85
Study 10348530 — intervention group
Group type: COMPARATOR
Intervention: Angiography + final IVUS assessment (group B)
Number of subjects: 85
Study 7573630 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month therapeutic community program
Number of subjects: 628